nach oben

Diabetologia

Erschienen in:

01.04.2008 | Article

Mice with beta cell overexpression of glycogen synthase kinase-3β have reduced beta cell mass and proliferation

verfasst von: Z. Liu, K. Tanabe, E. Bernal-Mizrachi, M. A. Permutt

Erschienen in: Diabetologia | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Glycogen synthase kinase-3 (GSK3) has been implicated in the pathophysiology of several prevalent diseases, including diabetes. However, despite recent progress in our understanding of the role of GSK3 in the regulation of glucose metabolism in peripheral tissues, the involvement of GSK3 in islet beta cell growth and function in vivo is unknown. We therefore sought to determine whether over-activation of GSK3β would lead to alterations in islet beta cell mass and/or function.

Methods

Transgenic mice overexpressing a constitutively active form of human GSK3β (S9A) under the control of the rat insulin promoter (RIP-GSK3βCA) were created. Studies using mouse insulinoma cells (MIN6) were conducted to investigate the regulation of GSK3β activity and its impact on pancreas/duodenum homeobox protein-1 (PDX-1) levels.

Results

We demonstrated that phosphorylation of GSK3β was decreased, indicating increased GSK3β activity in two animal models of diabetes, Lepr ^−/− mice and Ins2 ^Akita/+ mice. In MIN6 cells, the activity of GSK3β was regulated by glucose, in a fashion largely dependent on phosphatidylinositol 3-kinase. RIP-GSK3βCA transgenic mice showed impaired glucose tolerance after 5 months of age. Histological studies revealed that transgenic mice had decreased beta cell mass and decreased beta cell proliferation, with a 50% decrease (p < 0.05) in the level of PDX-1.

Conclusions/interpretation

We showed direct evidence that GSK3β activity is associated with beta cell failure in diabetic mouse models and that its overactivation resulted in decreased pancreatic beta cell proliferation and mass. GSK3 modulates PDX-1 stability in both cultured insulinoma cells and islets in vivo. These results may ultimately facilitate the development of potential therapeutic interventions targeting type 2 diabetes and/or islet transplantation.

Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 27:2444–2449PubMedCrossRef

Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812PubMedCrossRef

Biddinger SB, Kahn CR (2006) From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 68:123–158PubMedCrossRef

Lee YH, White MF (2004) Insulin receptor substrate proteins and diabetes. Arch Pharm Res 27:361–370PubMedCrossRef

Ueki K, Okada T, Hu J et al (2006) Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38:583–588PubMedCrossRef

Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150–157PubMedCrossRef

Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108:1631–1638PubMed

Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789PubMedCrossRef

Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175–1186PubMedCrossRef

10.

Woodgett JR (2001) Judging a protein by more than its name: GSK-3. Sci STKE 2001:RE12

11.

Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG (1996) Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proc Natl Acad Sci USA 93:10228–10233PubMedCrossRef

12.

Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG (1999) Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48:1662–1666PubMedCrossRef

13.

Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR (2000) Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263–271PubMedCrossRef

14.

Henriksen EJ, Dokken BB (2006) Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7:1435–1441PubMed

15.

Wagman AS, Johnson KW, Bussiere DE (2004) Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 10:1105–1137PubMedCrossRef

16.

Kaidanovich O, Eldar-Finkelman H (2002) The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 6:555–561PubMedCrossRef

17.

Clodfelder-Miller B, De Sarno P, Zmijewska AA, Song L, Jope RS (2005) Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 280:39723–39731PubMedCrossRef

18.

McManus EJ, Sakamoto K, Armit LJ et al (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J 24:1571–1583PubMedCrossRef

19.

Pearce NJ, Arch JR, Clapham JC et al (2004) Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism 53:1322–1330PubMedCrossRef

20.

Cline GW, Johnson K, Regittnig W et al (2002) Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 51:2903–2910PubMedCrossRef

21.

Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H (2003) Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305:974–980PubMedCrossRef

22.

Rao R, Hao CM, Redha R, Wasserman DH, McGuinness OP, Breyer MD (2007) Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia 50:452–460PubMedCrossRef

23.

Ring DB, Johnson KW, Henriksen EJ et al (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52:588–595PubMedCrossRef

24.

Girish V, Vijayalakshmi A (2004) Affordable image analysis using NIH Image/ImageJ. Indian J Cancer 41:47PubMed

25.

Martinez SC, Cras-Meneur C, Bernal-Mizrachi E, Permutt MA (2006) Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet β-cell. Diabetes 55:1581–1591PubMedCrossRef

26.

Ohsugi M, Cras-Meneur C, Zhou Y et al (2005) Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion. J Biol Chem 280:4992–5003PubMedCrossRef

27.

Dickson LM, Lingohr MK, McCuaig J et al (2001) Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 276:21110–21120PubMedCrossRef

28.

Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA (2002) Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol Endocrinol Metab 283:E784–E793PubMed

29.

Kitamura T, Nakae J, Kitamura Y et al (2002) The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839–1847PubMed

30.

Koster JC, Remedi MS, Flagg TP et al (2002) Hyperinsulinism induced by targeted suppression of beta cell KATP channels. Proc Natl Acad Sci USA 99:16992–16997PubMedCrossRef

31.

Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M (2006) Stabilization of beta-catenin impacts pancreas growth. Development 133:2023–2032PubMedCrossRef

32.

Boucher MJ, Selander L, Carlsson L, Edlund H (2006) Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. J Biol Chem 281:6395–6403PubMedCrossRef

33.

Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D (2006) Role of the forkhead protein FoxO1 in beta cell compensation to insulin resistance. J Clin Invest 116:775–782PubMedCrossRef

34.

Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA (2005) Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes 54:968–975PubMedCrossRef

35.

Mussmann R, Geese M, Harder F et al (2007) Inhibition of glycogen synthase kinase (GSK) 3 promotes replication and survival of pancreatic beta cells. J Biol Chem 282:12030–12037PubMedCrossRef

36.

Kushner JA, Ye J, Schubert M et al (2002) Pdx1 restores beta cell function in Irs2 knockout mice. J Clin Invest 109:1193–1201PubMed

37.

Surjit M, Lal SK (2007) Glycogen synthase kinase-3 phosphorylates and regulates the stability of p27kip1 protein. Cell Cycle 6:580–588PubMed

38.

Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511PubMedCrossRef

39.

Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG (1998) Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421:125–130PubMedCrossRef

40.

Drucker DJ (2007) The role of gut hormones in glucose homeostasis. J Clin Invest 117:24–32PubMedCrossRef

41.

Buteau J, Spatz ML, Accili D (2006) Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 55:1190–1196PubMedCrossRef

Titel: Mice with beta cell overexpression of glycogen synthase kinase-3β have reduced beta cell mass and proliferation
verfasst von: Z. Liu
K. Tanabe
E. Bernal-Mizrachi
M. A. Permutt
Publikationsdatum: 01.04.2008
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 4/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0914-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Self-monitoring of blood glucose in type 2 diabetes: a new look at published trials

A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice